Ronald Linnartz

1.7k total citations
22 papers, 786 citations indexed

About

Ronald Linnartz is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ronald Linnartz has authored 22 papers receiving a total of 786 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ronald Linnartz's work include Advanced Breast Cancer Therapies (6 papers), Fibroblast Growth Factor Research (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Ronald Linnartz is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Fibroblast Growth Factor Research (4 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Ronald Linnartz collaborates with scholars based in United States, Switzerland and Belgium. Ronald Linnartz's co-authors include Dennis J. Slamon, Fred Saad, Carsten Goessl, Yong-Jiang Hei, Marc Gittelman, Celestia S. Higano, Claude Schulman, Eric J. Small, Fairooz F. Kabbinavar and David L. Bilhartz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ronald Linnartz

22 papers receiving 767 citations

Peers

Ronald Linnartz

PRM

ONCOL

RNMI

Eren Demirhan United States

Fabian Zohren United States

Eleanor Gutteridge United Kingdom

Olga Martínez‐Sáez Spain

Lavina Bharwani Singapore

Karen J. Ferrante United States

Taizo Hirata Japan

Neelima Vidula United States

Peng Yuan China

Huamao Mark Lin United States

Eren Demirhan United States

Ronald Linnartz

678 ×1.3

PRM

290 ×0.8

ONCOL

201 ×0.8

219 ×1.2

RNMI

231 ×1.3

Citations per year, relative to Ronald Linnartz Ronald Linnartz (= 1×) peers Eren Demirhan

Countries citing papers authored by Ronald Linnartz

Since Specialization

Citations

This map shows the geographic impact of Ronald Linnartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Linnartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Linnartz more than expected).

Fields of papers citing papers by Ronald Linnartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Linnartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Linnartz. The network helps show where Ronald Linnartz may publish in the future.

Co-authorship network of co-authors of Ronald Linnartz

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Linnartz. A scholar is included among the top collaborators of Ronald Linnartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Linnartz. Ronald Linnartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Brien, Neil A., Martina S.J. McDermott, Dylan Conklin, et al.. (2020). Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Research. 22(1). 89–89. 87 indexed citations

Jayaraman, Pushpa, John M. Millholland, Neil A. O’Brien, et al.. (2019). Abstract C103: Targeting IL-1β pathway for cancer immunotherapy. Molecular Cancer Therapeutics. 18(12_Supplement). C103–C103. 3 indexed citations

O’Brien, Neil A., Dylan Conklin, Alex Gaither, et al.. (2019). Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models. 3825–3825. 1 indexed citations

O’Brien, Neil A., Martina S.J. McDermott, Dylan Conklin, et al.. (2019). Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models. Cancer Research. 79(13_Supplement). 3825–3825. 1 indexed citations

O’Brien, Neil A., Dylan Conklin, Tong Luo, et al.. (2017). Abstract 4150: Anti-tumor activity of the PI3K/mTOR pathway inhibitors alpelisib (BYL719) and everolimus (RAD001) in xenograft models of acquired resistance to CDK-4/6 targeted therapy. Cancer Research. 77(13_Supplement). 4150–4150. 4 indexed citations

Hurvitz, Sara A., Ondrej Kalous, Dylan Conklin, et al.. (2015). In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Research and Treatment. 149(3). 669–680. 46 indexed citations

Tomaso, Emmanuelle di, Ronald Linnartz, Fang Li, Cristian Massacesi, & Samit Hirawat. (2015). Abstract 4698: Combination of ceritinib (LDK378) with PI3K inhibitors (buparlisib [BKM120] and alpelisib [BYL719]) demonstrates synergistic preclinical antitumor activity in ALK-rearranged non-small cell lung cancer (NSCLC). Cancer Research. 75(15_Supplement). 4698–4698. 1 indexed citations

O’Brien, Neil A., Tong Luo, Erika von Euw, et al.. (2014). Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research. 20(13). 3507–3520. 93 indexed citations

Hamidi, Habib, Ming Lu, Lee Anderson, et al.. (2014). KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. British Journal of Cancer. 111(9). 1788–1801. 42 indexed citations

10.

O’Brien, Neil A., Emmanuelle di Tomaso, Raul Ayala, et al.. (2014). Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. Cancer Research. 74(19_Supplement). 4756–4756. 38 indexed citations

11.

Euw, Erika M. von, Hong-Mei Rong, Neil A. O’Brien, et al.. (2013). Abstract 2437: MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status.. Cancer Research. 73(8_Supplement). 2437–2437. 1 indexed citations

12.

Euw, Erika von, Douglas S. Conklin, Ondrej Kalous, et al.. (2012). Abstract P4-08-01: PI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKT. Cancer Research. 72(24_Supplement). P4–8. 2 indexed citations

13.

Huynh, Hung, Pierce K. H. Chow, Su Pin Choo, et al.. (2011). Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. Journal of Hepatology. 56(3). 595–601. 48 indexed citations

14.

Konecny, Gottfried E., Boris Winterhoff, Jingwei Qi, et al.. (2011). Abstract 3589: Dovitinib (TKI258), a multikinase inhibitor of FGFR, PDGFR, and VEGFR tyrosine kinases, induces growth inhibition in endometrial carcinoma cells. Cancer Research. 71(8_Supplement). 3589–3589. 5 indexed citations

15.

Shi, Michael, Ronald Linnartz, Richard Versace, et al.. (2011). Abstract 3575: Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer. Cancer Research. 71(8_Supplement). 3575–3575. 2 indexed citations

16.

Linnartz, Ronald, et al.. (2011). P3-17-11: Dovitinib (TKI258), a Dual Inhibitor of FGFR and VEGFR, Induces Tumor Growth Suppression in Xenograft Models of Primary Human Breast Cancer.. Cancer Research. 71(24_Supplement). P3–17. 2 indexed citations

17.

Gardner, Humphrey, Paolo Nucíforo, Ciara Barrett, et al.. (2009). PI3 Kinase Pathway Analysis in Tissue Microarrays Using Laser Capture Microdissection and Immunohistochemistry.. Cancer Research. 69(24_Supplement). 4043–4043. 2 indexed citations

18.

Smith, Matthew R., Fairooz F. Kabbinavar, Fred Saad, et al.. (2005). Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology. 23(13). 2918–2925. 377 indexed citations

19.

Ali, Suhail M., Kim Leitzel, Walter P. Carney, et al.. (2004). Pretreatment serum uPA and survival in patients with advanced pancreatic cancer. Journal of Clinical Oncology. 22(14_suppl). 4247–4247. 2 indexed citations

20.

Zhou, Honghui, Henry Lau, Elisabeth G.E. de Vries, et al.. (2000). Population Pharmacokinetics/Toxicodynamics (PK/TD) Relationship of SAM486A in Phase I Studies in Patients with Advanced Cancers. The Journal of Clinical Pharmacology. 40(3). 275–283. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact